Table 3.
Group 1 (n=9) | Group 2 (n=16) | Group 3 (n=7) | |
---|---|---|---|
Leukocytes (109/l) | 8.41 ± 1.83 | 9.89 ± 3.36 | 9.94 ± 2.83 |
RBCs (1012/l) | 3.02 ± 0.78 | 2.83 ± 0.67 | 2.75 ± 0.35 |
Hb (g/100 ml) | 8.46 ± 1.26 | 8.42 ± 1.61 | 8.96 ± 0.99 |
MCV (fl) | 81.66 ± 13.51 | 83.63 ± 6.08 | 90.74 ± 6.92 |
MCH (pg) | 28.99 ± 5.51 | 30.16 ± 2.55 | 32.74 ± 2.78 |
Platelets count (109/l) | 370.78 ± 112.98 | 344.56 ± 129.92 | 405.29 ± 143.30 |
Polynuclear Neutrophils (109/l) | 4.18 ± 1.29 | 4.97 ± 1.91 | 5.53 ± 2.82 |
Eosinophils (109/l) | 0.27 ± 0.15 | 0.33 ± 0.23 | 0.30 ± 0.18 |
Lymphocytes (109/l) | 2.91 ± 0.63 | 3.27 ± 1.27 | 2.93 ± 1.24 |
Monocytes (109/l) | 0.99 ± 0.33 | 1.23 ± 0.59 | 1.11 ± 0.35 |
Reticulocytes (%) | 6.90 ± 2.47 | 7.61 ± 2.47 | 8.70 ± 3.44 |
Lactate dehydrogenase (UI/l) | 440.44 ± 104.98 | 480.14 ± 136.76 | 437.33 ± 136.59 |
Hct (%) | 26.41 ± 3.92 | 26.01 ± 5.61 | 26.50 ± 4.70 |
ηb at 90s−1(mPa/s | 9.03 ± 2.59 | 7.21 ± 2.00 | 8.29 ± 2.69 |
EI at 0.95 Pa | 0.06 ± 0.03 | 0.05 ± 0.04 | 0.05 ± 0.04 |
EI at 1.69 Pa | 0.12 ± 0.04 | 0.10 ± 0.05 | 0.11 ± 0.05 |
EI at 3 Pa | 0.19 ± 0.05 | 0.15 ± 0.06 | 0.17 ± 0.06 |
EI at 5.33 Pa | 0.26 ± 0.06 | 0.22 ± 0.08 | 0.23 ± 0.07 |
EI at 9.49 Pa | 0.32 ± 0.07 | 0.28 ± 0.10 | 0.30 ± 0.09 |
EI at 16.87 Pa | 0.38 ± 0.08 | 0.32 ± 0.11 | 0.36 ± 0.10 |
EI at 30 Pa | 0.42 ± 0.09 | 0.36 ± 0.11 | 0.40 ± 0.11 |
AI (%) | 57.96 ± 8.03 | 52.51 ± 7.31 | 53.75 ± 11.39 |
γthr (s−1) | 258.89 ± 81.50 | 268.20 ± 120.51 | 346.43 ± 251.29 |
Group 1: without sickle cell retinopathy, group 2: non-proliferative and proliferative stage I and II retinopathy, group 3: proliferative retinopathy of stage III, IV and V. Mean ± SD. RBCs = red blood cells, Hb = hemoglobin concentration, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, Hct = hematocrit, ηb = whole blood viscosity, EI = Elongation Index (i.e. RBC deformability), AI = RBC aggregation index, γthr = RBC disaggregation threshold.